No Data
No Data
Gilead, GSK Could Be Impacted by Potential HHS HIV Prevention Cuts
4 Analysts Assess Pfizer: What You Need To Know
Trump Administration Follows Biden in Defending 340B Drug-discount Program
Merck & Co's Options: A Look at What the Big Money Is Thinking
Alpha Cognition Is 'Under-Followed' As Alzheimer Drug Targets $2 Billion Long Term Care Market: Analyst
RFK Jr. to Meet With Execs of Infant Formula Makers - Report